Bristol-Myers Squibb BMY Zeposia — Total Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's zeposia — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bristol-Myers Squibb's zeposia — total revenues?
- Bristol-Myers Squibb (BMY) reported zeposia — total revenues of $169M in Q2 2026.
- How has Bristol-Myers Squibb's zeposia — total revenues changed year-over-year?
- Bristol-Myers Squibb's zeposia — total revenues increased by 12.7% year-over-year, from $150M to $169M.
- What is the long-term trend for Bristol-Myers Squibb's zeposia — total revenues?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's zeposia — total revenues has grown at a 44.1% compound annual growth rate (CAGR), from $134M to $577M.
- What does zeposia — total revenues mean?
- This metric represents the total global net sales generated from the commercialization of Zeposia, a sphingosine-1-phosphate receptor modulator used primarily for the treatment of multiple sclerosis and ulcerative colitis. As a key growth asset within the company's immunology portfolio, this revenue stream reflects the drug's market penetration, physician adoption rates, and competitive positioning against other oral therapies. Monitoring this figure is essential for assessing the company's success in expanding its footprint in the autoimmune disease market.